Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MindWalk Holdings ( (HYFT) ) just unveiled an update.
On March 12, 2026, MindWalk Holdings reported Q3 fiscal 2026 results for the period ended January 31, 2026, posting revenue of C$4.2 million, up 52% year over year and marking a third straight quarter of revenue growth, with U.S. sales doubling to C$2.6 million. The company also improved year-to-date gross margin to 58% and narrowed its quarterly net loss from continuing operations to C$3.9 million, while maintaining C$14.2 million in cash and equivalents.
MindWalk secured its first one-year enterprise LensAI platform contract with its largest AI client, shifting part of its business mix toward contracted recurring revenue and supporting its strategic push into North America, including new biologics services in Boston and Cambridge and the divestiture of European operations. Operationally it launched the B cell Llama nanobody discovery platform, advanced vaccine and therapeutic programs in dengue, GLP-1 and influenza based on LensAI-derived epitopes and pathways, and engaged advisors to structure asset-level financing around key pipeline assets, moves that collectively strengthen its AI-biologics positioning and create new funding and commercialization avenues for stakeholders.
The most recent analyst rating on (HYFT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.
Spark’s Take on HYFT Stock
According to Spark, TipRanks’ AI Analyst, HYFT is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and negative cash flow) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improved gross margin, and a stronger cash position, but valuation remains constrained by negative earnings.
To see Spark’s full report on HYFT stock, click here.
More about MindWalk Holdings
MindWalk Holdings Corp. (Nasdaq: HYFT) is a Bio-Native AI company specializing in biologics discovery and AI-driven drug development. Its proprietary HYFT biological pattern system and LensAI platform analyze conserved functional subsequences to uncover drug targets and candidates beyond the reach of conventional sequence-based methods, supported by operations in North America and Europe through subsidiaries focused on biologics and therapeutics.
Average Trading Volume: 551,535
Technical Sentiment Signal: Sell
Current Market Cap: $59.76M
Find detailed analytics on HYFT stock on TipRanks’ Stock Analysis page.